Patient selection for phase II trials

American Journal of Clinical Oncology: Cancer Clinical Trials

Volumn 32, Issue 2, 2009, Pages 216-219

  Sonpavde, Guru ^a,b,c,e   Galsky, Matthew D ^b   Hutson, Thomas E ^a,b   Von Hoff, Daniel D ^d  

^a TEXAS ONCOLOGY   (United States)

^b US Oncology Research   (United States)

^c BAYLOR COLLEGE OF MEDICINE   (United States)

^d UNIVERSITY OF ARIZONA   (United States)

^e Developmental Therapeutics Committee and Co Chair of the Genitourinary Committee   (United States)

Author keywords

Patient selection; Phase II trial

Indexed keywords

CALCITRIOL; CARBOPLATIN; CISPLATIN; CORTICOSTEROID; DOCETAXEL; GEMCITABINE; MITOXANTRONE; PACLITAXEL;

CANCER CHEMOTHERAPY; CLINICAL TRIAL; CONTENT VALIDITY; DRUG EFFICACY; DRUG MEGADOSE; HUMAN; METHODOLOGY; PATIENT SELECTION; PHASE 2 CLINICAL TRIAL; POPULATION DYNAMICS; PROSTATE CANCER; RANDOMIZATION; RANDOMIZED CONTROLLED TRIAL; REPRODUCIBILITY; REVIEW; TREATMENT WITHDRAWAL; UROGENITAL TRACT TUMOR;

CLINICAL TRIALS, PHASE II AS TOPIC; HUMANS; PATIENT SELECTION;

EID: 67749104038     PISSN: 02773732     EISSN: 1537453X     Source Type: Journal    
DOI: 10.1097/COC.0b013e318172dccd     Document Type: Review

References (41)

1. Korn EL, Arbuck SG, Pluda JM, et al. Clinical trial designs for cytostatic agents: are new approaches needed? J Clin Oncol. 2001;19:265-272.
2. Simon RM, Steinberg SM, Hamilton M, et al. Clinical trial designs for the early clinical development of therapeutic cancer vaccines. J Clin Oncol. 2001;19:1848-1854.
3. Estey EH, Thall PF. New designs for phase II clinical trials. Blood. 2003; 102:442-448.
4. Van Glabbeke M, Steward W, Armand JP, et al. Non-randomised phase II trials of drug combinations: often meaningless, sometimes misleading. Are there alternative strategies? Eur J Cancer. 2002;38:635- 638.
5. Wieand HS. Randomized phase II trials: what does randomization gain? J Clin Oncol. 2005;23:1794-1795.
6. Zia MI, Siu LL, Pond GR, et al. Comparison of outcomes of phase II studies and subsequent randomized controlled studies using identical chemotherapeutic regimens. J Clin Oncol. 2005;23:6982-6991.
7. Kindler HL, Friberg G, Singh DA, et al. Phase II trial of bevacizumab plus gemcitabine in patients with advanced pancreatic cancer. J Clin Oncol. 2005;23:8033-8040.
8. Kindler HL, Niedzwiecki D, Hollis D, et al. A double-blind, placebocontrolled, randomized phase III trial of gemcitabine (G) plus bevacizumab (B) versus gemcitabine plus placebo (P) in patients (pts) with advanced pancreatic cancer (PC): a preliminary analysis of Cancer and Leukemia Group B (CALGB) 80303. Proc Gastrointestinal Cancer Symposium. 2007; abstract 108.
9. Moore MJ, Hamm J, Dancey J, et al. Comparison of gemcitabine versus the matrix metalloproteinase inhibitor BAY 12-9566 in patients with advanced or metastatic adenocarcinoma of the pancreas: a phase III trial of the National Cancer Institute of Canada Clinical Trials Group. J Clin Oncol. 2003;21: 3296-3302.
10. Van Cutsem E, van de Velde H, Karasek P, et al. Phase III trial of gemcitabine plus tipifarnib compared with gemcitabine plus placebo in advanced pancreatic cancer. J Clin Oncol. 2004;22:1430-1438.
11. Giaccone G, Herbst RS, Manegold C, et al. Phase III clinical trial of gefitinib, an epidermal growth factor receptor inhibitor, in combination with gemcitibine and cisplatin in advanced non-small-cell lung cancer: INTACT 1. J Clin Oncol. 2004;22:777-784.
12. Herbst RS, Giaccone G, Schiller JH, et al. Gefitinib in combination with paclitaxel and carboplatin in advanced non-small-cell lung cancer: a phase III trial-INTACT 2. J Clin Oncol. 2004;22:785-794.
13. Foo KF, Tan EH, Leong SS, et al. Gemcitabine in metastatic nasopharyngeal carcinoma of the undifferentiated type. Ann Oncol. 2002;13:150 -156.
14. Tan SB, Machin D, Tai BC, et al. A Bayesian re-assessment of two phase II trials of gemcitabine in metastatic nasopharyngeal cancer. Br J Cancer. 2002;86:843-850.
15. Tan SB, Machin D. Phase II trial designs in the presence of stratification. Stat Med. 2006;25:3220-3222; author reply, 3222-3223.
16. Bajorin D. The phase III candidate: can we improve the science of selection? J Clin Oncol. 2004;22:211-213.
17. Verbel DA, Kelly WK, Smaletz O, et al. Estimating survival benefit in castrate metastatic prostate cancer: decision making in proceeding to a definitive phase III trial. Urology. 2003;61:142-144.
18. Mick R, Crowley JJ, Carroll RJ. Phase II clinical trial design for noncytotoxic anticancer agents for which time to disease progression is the primary endpoint. Control Clin Trials. 2000;21:343-359.
19. Fleming TR. Standard versus adaptive monitoring procedures: a commentary. Stat Med. 2006;25:3305-3312.
20. Bajorin DF, Dodd PM, Mazumdar M, et al. Long-term survival in metastatic transitional-cell carcinoma and prognostic factors predicting outcome of therapy. J Clin Oncol. 1999;17:3173-3181.
21. Linardou H, Aravantinos G, Efstathiou E, et al. Gemcitabine and carboplatin combination as first-line treatment in elderly patients and those unfit for cisplatin-based chemotherapy with advanced bladder carcinoma: phase II study of the Hellenic Co-operative Oncology Group. Urology. 2004;64:479-484.
22. Nogue-Aliguer M, Carles J, Arrivi A, et al. Gemcitabine and carboplatin in advanced transitional cell carcinoma of the urinary tract: an alternative therapy. Cancer. 2003;97:2180-2186.
23. Hussain M, Vaishampayan U, Du W, et al. Combination paclitaxel, carboplatin, and gemcitabine is an active treatment for advanced urothelial cancer. J Clin Oncol. 2001;19:2527-2533.
24. Lee JJ, Feng L. Randomized phase II designs in cancer clinical trials: current status and future directions. J Clin Oncol. 2005;23:4450-4457.
25. Stone A, Wheeler C, Barge A. Improving the design of phase II trials of cytostatic anticancer agents. Contemp Clin Trials. 2007;28:138 -145.
26. Simon R, Wittes RE, Ellenberg SS, et al. Randomized phase II clinical trials. Cancer Treat Rep. 1985;69:1375-1381.
27. Liu PY, LeBlanc M, Desai M. False positive rates of randomized phase II designs. Control Clin Trials. 1999;20:343-352.
28. Fleming TR, Richardson BA. Some design issues in trials of microbicides for the prevention of HIV infection. J Infect Dis. 2004;190:666-674.
29. Rosner GL, Stadler W, Ratain MJ. Randomized discontinuation design: application to cytostatic antineoplastic agents. J Clin Oncol. 2002;20:4478 -4484.
30. Capra WB. Comparing the power of the discontinuation design to that of the classic randomized design on time-to-event endpoints. Control Clin Trials. 2004;25:168-177.
31. Freidlin B, Simon R. Evaluation of randomized discontinuation design. J Clin Oncol. 2005;23:5094-5098.
32. Sonpavde G, Hutson TE, Galsky MD, et al. Problems with the randomized discontinuation design. J Clin Oncol. 2006;24:4669-4670.
33. Booth B, Zemmel R. Prospects for productivity. Nat Rev Drug Discov. 2004;3:451-456.
34. Bellmunt J, Guillem V, Paz-Ares L, et al. Phase I-II study of paclitaxel, cisplatin, and gemcitabine in advanced transitional-cell carcinoma of the urothelium. Spanish Oncology Genitourinary Group. J Clin Oncol. 2000;18: 3247-3255.
35. Bellmunt J, de Wit R, Albiol S, et al. New drugs and new approaches in metastatic bladder cancer. Crit Rev Oncol Hematol. 2003;47:195-206.
36. Bellmunt J, von der Maase H, Mead GM, et al. Randomized phase III study comparing paclitaxel/cisplatin/gemcitabine (PCG) and gemcitabine/cisplatin (GC) in patients with locally advanced (LA) or metastatic (M) urothelial cancer without prior systemic therapy; EORTC30987/Intergroup Study. J Clin Oncol. 2007 ASCO Annual Meeting Proceedings 25 (18S): LBA5030.
37. Beer TM, Eilers KM, Garzotto M, et al. Weekly high-dose calcitriol and docetaxel in metastatic androgen-independent prostate cancer. J Clin Oncol. 2003;21:123-128.
38. Beer TM, Ryan CW, Venner PM, et al. Double-blinded randomized study of high-dose calcitriol plus docetaxel compared with placebo plus docetaxel in androgen-independent prostate cancer: a report from the ASCENT Investigators. J Clin Oncol. 2007;25:669-674.
39. Novacea press release, November 5, 2007.
40. Tannock IF, de Wit R, Berry WR, et al. Docetaxel plus prednisone or mitoxantrone plus prednisone for advanced prostate cancer. N Engl J Med. 2004;351:1502-1512.
41. Petrylak DP, Tangen CM, Hussain MH, et al. Docetaxel and estramustine compared with mitoxantrone and prednisone for advanced refractory prostate cancer. N Engl J Med. 2004;351:1513-1520.